Enzalutamide

The FDA expanded the approval of enzalutamide for prostate cancer.

The FDA announced several regulatory actions the past few weeks.

Several practice-changing clinical trials in recent years have led to the understanding that combination treatments are most effective for patients with advanced prostate cancer.

FDA approved talazoparib plus enzalutamide for treatment of homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer.

CHICAGO — Adding talazoparib to enzalutamide reduced the risk for disease progression or death by 55% in certain men with metastatic castration-resistant prostate cancer, results of the randomized phase 3 TALAPRO-2 trial showed.

The addition of enzalutamide to androgen deprivation therapy extended metastasis-free survival among men with nonmetastatic, hormone-sensitive prostate cancer with high-risk biochemical recurrence, according to study results.

In this video, Shilpa Gupta, MD, Director of the Director of the Genitourinary Medical Oncology at Taussig Cancer Institute, discusses data presented from the TALAPRO-2 trial, presented at ASCO Genitourinary Cancers Symposium.

In this video, Shilpa Gupta, MD, Director of Genitourinary Medical Oncology at Taussig Cancer Institute, discusses data from the TRITON3 trial presented at ASCO Genitourinary Cancers Symposium.

A combination of enzalutamide and leuprolide significantly extended metastasis-free survival for men with nonmetastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence, according to a company press release.

Two phase 3 trials evaluating pembrolizumab in combination with additional agents failed to meet their primary endpoints, according to the agent’s manufacturer.